294 related articles for article (PubMed ID: 26897942)
1. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
3. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
4. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
5. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
[TBL] [Abstract][Full Text] [Related]
6. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.
Wang RF; Song BR; Peng JJ; Cai GX; Liu FQ; Wang MH; Cai SJ; Ye X
Hepatogastroenterology; 2014 Jun; 61(132):994-9. PubMed ID: 26158155
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
9. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
[TBL] [Abstract][Full Text] [Related]
10. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
11. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of serum anti-p53 antibody as a monitoring marker in colorectal cancer].
Amano K; Kumamoto K; Kuwabara K; Ishiguro T; Ohsawa T; Okada N; Kumagai Y; Baba H; Ishibashi K; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2170-2. PubMed ID: 23268013
[TBL] [Abstract][Full Text] [Related]
13. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
14. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
16. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
[TBL] [Abstract][Full Text] [Related]
17. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of perioperative change of CEA level in colorectal patients when pre-operative level is normal.
Lan YT; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Yang SH
Hepatogastroenterology; 2012 May; 59(115):717-20. PubMed ID: 22024225
[TBL] [Abstract][Full Text] [Related]
19. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
20. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer.
Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC
Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
